ASCO News In Brief: Hoechst Marion Roussel Anzemet
Executive Summary
Hoechst Marion Roussel Anzemet: Oral dolasetron mesylate for prevention of acute nausea and vomiting after moderately emetogenic platinum-containing chemotherapy may be optimal at 200 mg dose, according to dose-response data from a 307-patient trial presented at the American Society of Clinical Oncology meeting in Philadelphia May 18-21. The drug is administered 30 minutes prior to chemotherapy. A complete response rate of 73% was reported in the 200 mg dolasetron arm, compared to a 40% CR in the 25 mg arm; 61% of patients receiving 200 mg had no nausea versus 35% of those receiving 25 mg. An NDA for Anzemet was submitted in April...